Cardiac expression of adiponectin and its receptors in streptozotocin-induced diabetic rats

Metabolism: Clinical and Experimental

Volumn 56, Issue 10, 2007, Pages 1363-1371

  Guo, Zhixin ^a,b   Xia, Zhengyuan ^a   Yuen, Violet G ^a   McNeill, John H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ALPHA; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INTERLEUKIN 6; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INFLAMMATION; INSULIN RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RADIOIMMUNOASSAY; RAT; RECEPTOR UPREGULATION; SARCOLEMMA; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ACETYL-COA CARBOXYLASE; ADIPONECTIN; ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TRANSPORTER TYPE 4; HEART FUNCTION TESTS; INTERLEUKIN-6; MALE; MULTIENZYME COMPLEXES; MYOCARDIUM; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, WISTAR; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548603601     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.05.005     Document Type: Article

References (56)

1. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21 (1998) 296-309
2. Cai L., and Kang Y.J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 1 (2001) 181-193
3. Cullen P., von Eckardstein A., Souris S., Schulte H., and Assmann G. Dyslipidaemia and cardiovascular risk in diabetes. Diabetes Obes Metab 1 (1999) 189-198
4. Biondi-Zoccai G.G., Abbate A., Liuzzo G., and Biasucci L.M. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41 (2003) 1071-1077
5. Rodrigues B., Cam M.C., and McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180 (1998) 53-57
6. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocytes secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
7. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 257 (1999) 79-83
8. Daimon M., Oizumi T., Saitoh T., Wataru K., Akihiko H., Hiroshi Y., et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 26 (2003) 2015-2020
9. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
10. Tentolouris N., Doulgerakis D., Moyssakis I., Kyriaki D., Makrilakis K., Kosmadakis G., et al. Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 36 (2004) 721-727
11. Perseghin G., Lattuada G., Danna M., Sereni L.P., Maffi P., Cobelli F.D., et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 285 (2003) E1174-E1181
12. Piñeiro R., Iglesias M.J., Gallego R., Raghay K., Eiras S., Rubio J., et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579 (2005) 5163-5169
13. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
14. Winder W.W., and Hardie D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277 (1999) E1-E10
15. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10 (2004) 1384-1389
16. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2004) 762-769
17. Inukai K., Nakashima Y., Watanable M., Takata N., Sawa T., Kurihara S., et al. Regulation of adiponectin receptor gene expression in diabetic mice. Am J Physiol Endocrinol Metab 288 (2005) E876-E882
18. Tsuchida A., Yamauchi T., Ito Y., Hada Y., Maki T., Takekawa S., et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279 (2004) 30817-30822
19. Steinmetz M., Quentin T., Poppe A., Paul T., and Jux C. Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac development of the rat. Basic Res Cardiol 100 (2005) 263-269
20. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemn J., Youker K., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18 (2004) 1692-1700
21. Gwechenberger M., Mendoza L.H., Youker K.A., Frangogiannis N.G., Smith C.W., Michael L.H., et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulaton 99 (1999) 546-551
22. Hogye M., Mandi Y., Csanady M., Sepp R., and Buzas K. Comparisons of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 94 (2004) 249-251
23. Song Y., Wang J., Li Y., Du Y., Arteel G.E., Saari J.T., et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol 167 (2005) 17-26
24. Mohamed-Ali V., Armstrong L., Clarker D., Bolton C.H., and Pinkney J.H. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes. J Intern Med 250 (2001) 415-421
25. Hotamisligil G.S., and Spiegelman B.M. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43 (1994) 1271-1278
26. Nilsson J., Jovinge S., Niemann A., Reneland R., and Lithell H. Relation between plasma tumor necrosis factor-α and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 18 (1998) 1199-1202
27. Burger A.J., and Aronson D. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. Int J Cardiol 81 (2001) 243-249
28. Jialal I., Devaraj S., and Venugopal S.K. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha-tocopherol therapy. Free Radic Res 36 (2002) 1331-1336
29. Lee Y.T., Hsu C.C., Lin M.H., Liu K.S., and Yin M.C. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 513 (2005) 145-150
30. Mann D.L. Tumor necrosis factor-induced signal transduction and left ventricular remodeling. J Card Fail 8 (2002) S379-S386
31. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
32. Yuen V.G., Orvig C., Thompson K.H., and McNeill J.H. Improvement in cardiac dysfunction in STZ-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). Can J Physiol Pharmacol 71 (1993) 270-276
33. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
34. Folch J.M., Lees M., and Stanley G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226 (1957) 497-509
35. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 (1996) 286-289
36. Hadjadj S., Aubert R., Fumeron F., Pean F., Tichet J., Roussel R., et al. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia 48 (2005) 1088-1092
37. Imagawa A., Funahashi T., Nakamura T., Moriwaki M., Tanada S., Nishizawa H., et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 25 (2002) 1665-1666
38. Frystyk J., Tarnow L., Krarup T., Hansen H.H., and Parving A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48 (2005) 1911-1918
39. Thule P.M., Campbell A.G., Kleinhenz D.J., Olson D.E., Boutwell J.J., Sutliff R.L., et al. Hepatic insulin gene therapy prevents deterioration of vascular function and improves adipcytokine profile in STZ-diabetic rats. Am J Physiol Endocrinol Metab 290 (2006) E114-E122
40. Nedvidkova J., Smitka K., Kopsky V., and Hainer V. Adiponectin, an adipocyte-derived protein. Physiol Res 54 (2005) 133-140
41. Hu X., Sato J., Oshida Y., Xu M., Bjotto G., and Sato Y. Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 59 (2003) 103-111
42. Bauche I.B., Ait El Mkadem S., Rezsohazy R., Funahashi T., Maeda N., Miranda L.M., et al. Adiponectin downregulates its own production and the expression of its AdipoR2 receptor in transgenic mice. Biochem Biophys Res Commun 345 (2006) 1414-1424
43. Fujioka D., Kawabata K., Saito Y., Kobayashi T., Nakamura T., Kodama Y., et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infracted heart. Am J Physiol Heart Circ Physiol 290 (2006) H2409-H2416
44. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
45. Kudo N., Barr A.J., Barr R.L., Desai S., and Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270 (1995) 17512-17520
46. Liao Y., Takashima S., Maeda N., Ouchi N., Komamura K., Shimomura I., et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67 (2005) 705-713
47. Mueckler M. Family of glucose transporter genes. Implications for glucose homeostasis and diabetes. Diabetes 39 (1990) 6-11
48. Russell R.R., Bergeron R., Shulman G.I., and Young L.H. Translocation of myocardial GLUT4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol Heart Circ Physiol 277 (1999) H643-H649
49. Burcelin R., Printz R.L., Kande J., Assan R., Granner D.K., and Girard J. Regulation of glucose transporter and hexokinase II expression in tissues of diabetic rats. Am J Physiol 265 (1993) E392-E401
50. Garvey W.T., Hardin D., Juhaszova M., and Dominguez J.H. Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am J Physiol 264 (1993) H837-H844
51. Katz E.B., Stenbit A.E., Hatton K., Depinho R., and Charron M.J. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377 (1995) 151-155
52. Abel E.D., Kaulbach H.C., Tian R., Hopkins J.C., Duffy J., Doestschman T., et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 104 (1999) 1703-1714
53. Stenbit A.E., Tsao T.S., Li J., Burcelin R., Geenen D.L., Factor S.M., et al. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 3 (1997) 1096-1101
54. Tsao T.S., Stenbit A.E., Factor S.M., Chen W., Rossetti L., and Charron M.J. Prevention of insulin resistance and diabetes in mince heterozygous for GLUT4 ablation by transgenic complementation of GLUT4 in skeletal muscle. Diabetes 48 (1999) 775-782
55. Allard M.F., Parsons H.L., Saeedi R., Wambolt R.B., and Brownsey R. AMPK and metabolic adaptation by the heart to pressure overload. Am J Physiol Heart Circ Physiol 292 (2007) H140-H148
56. Kewalramani G., An D., Kim M.S., Ghosh S., Qi D., Abrahani A., et al. AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. J Mol Cell Cardiol 42 (2007) 333-342